Home
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors.

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors.

Today’s Highlights January 8, 2025

Compugen

 January 8, 2025, Compugen (CGEN), announced that the first patient was dosed in a Phase 1 clinical trial with COM503, a potential first-in-class antibody against IL-18 binding protein licensed by Compugen to Gilead. Compugen is responsible for running the Phase 1 trial.

This Phase 1 multi-center dose escalation and dose expansion trial will evaluate the safety, tolerability . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights January 8, 2025

Other Articles